Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Boston Scientific (BSX) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareMedical DevicesBSX

Latest price · Nov 20, 2026 $42.72 -0.6% on the day · -55.8% over 12 months 52-week range $41.58 – $101.58
Get BSX alerts
Open-market purchases5 insiders$10.0M · last 12 months
Insiders selling2last 12 months
Reported sales$16.8M11 of 11 recent sales pre-planned (10b5-1)
In 15 seconds

Insiders put their own money in: $10.0M of open-market buys against $16.8M of sales. See how similar setups did below.

Past insider buys here: 0 of 7 beat the S&P 500 over the next 90 days. See each one ↓

Label: Strong buying · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • 90-day result for Susan E. Morano's $100K buy: in on Nov 24, 2026. See the 7- and 30-day results ↓
  • Next earnings expected around Feb 3, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Purchase Susan E. Morano, Director bought 2,040 shares at $49.22 ($100K).

Trade date
Aug 25, 2026
Disclosed to the SEC
Aug 26, 2026
Type
Open-market purchase (code P)

Read the original SEC filing ↗All BSX insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

BSX insider transactions (Form 4)

Open-market purchases and sales. 118 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Aug 26SEC Susan E. MoranoDirectorFirst buy Buy 2,04013,784 held (+17%) $49.22 $100K -13.2% —
Aug 7SEC David C. HabigerDirectorPast buys 0/2 beat S&P Buy 2,10017,160 held (+14%) $47.59 $100K -10.2% 34
Aug 5SEC Michael F. MahoneyCEO, PresidentFirst buyPast buys 1/3 beat S&P Buy 186,2401,590,024 held (+13%) $48.33 $9.0M -11.6% —
Aug 5SEC David C. HabigerDirectorPast buys 0/2 beat S&P Buy 1,04214,920 held (+8%) $48.07 $50K -11.1% 34
Aug 5SEC David C. HabigerDirectorPast buys 0/2 beat S&P Buy 14015,060 held (+1%) $48.59 $7K -12.1% 34
Aug 3SEC Edward J. LudwigDirectorPast buys 4/7 beat S&P Buy 5,00030,359 held (+20%) $45.48 $227K -6.1% 33
May 21SEC Edward J. LudwigDirectorFirst buyPast buys 4/7 beat S&P Buy 3,58025,359 held (+16%) $56.68 $203K -24.6% 33
May 21SEC David C. HabigerDirectorFirst buyPast buys 0/2 beat S&P Buy 2,25013,878 held (+19%) $55.92 $126K -23.6% 34
May 21SEC David C. HabigerDirectorFirst buyPast buys 0/2 beat S&P Buy 2,20011,628 held (+23%) $56.95 $125K -25.0% 34
May 21SEC Cheryl PegusDirectorFirst buyNew position Buy 1,770new position $56.49 $100K -24.4% —
Feb 3SEC Michael F. MahoneyCEO, President Sell Plan 159,7011,411,735 held (−10%) $93.49 $14.9M -54.3% —
Feb 3SEC Michael F. MahoneyCEO, President Sell Plan 1,2001,571,436 held (−0%) $94.06 $113K -54.6% —
Dec 2SEC Arthur C. ButcherEvp& Grp Pres, Medsurg & Apac Sell Plan 17,31323,600 held (−42%) $101.55 $1.8M -57.9% —
Nov 6SEC Ellen M. ZaneDirector Sell Plan 12,89124,134 held (−35%) $98.28 $1.3M -56.5% —
Nov 4SEC Joseph Michael FitzgeraldEvp & Group Pres, Cardiology Sell Plan 29,472178,342 held (−14%) $99.14 $2.9M -56.9% —
Nov 4SEC Joseph Michael FitzgeraldEvp & Group Pres, Cardiology Sell Plan 16,928207,814 held (−8%) $99.76 $1.7M -57.2% —
Nov 4SEC Joseph Michael FitzgeraldEvp & Group Pres, Cardiology Sell Plan 3,600224,742 held (−2%) $100.75 $363K -57.6% —
Oct 28SEC Ellen M. ZaneDirector Sell Plan 9,99027,035 held (−27%) $101.13 $1.0M -57.8% —
Oct 28SEC Ellen M. ZaneDirector Sell Plan 2,90124,134 held (−11%) $102.24 $297K -58.2% —
Oct 1SEC Joseph Michael FitzgeraldEvp & Group Pres, Cardiology Sell Plan 41,755178,342 held (−19%) $98.38 $4.1M -56.6% —
Oct 1SEC Joseph Michael FitzgeraldEvp & Group Pres, Cardiology Sell Plan 8,245220,097 held (−4%) $98.91 $816K -56.8% —
Historical context

Similar past setups: not applicable. There aren't enough comparable past cases for BSX's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with BSX in the Research Lab

Pre-set to BSX's latest insider buy of $10K or more (Aug 26, 2026: Susan E. Morano, $100K). Tap to change anything.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

BSX closeInsider buyInsider sale
406080100120DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-04EEarnings release filed 2026-04-22EEarnings release filed 2026-07-29EEarnings release filed 2026-10-28Bought $6,802 on 2026-08-04 · David C. HabigerBought $99,937 on 2026-08-05 · David C. HabigerBought $100,408 on 2026-08-25 · Susan E. MoranoBought $125,279 on 2026-05-19 · David C. HabigerBought $227,400 on 2026-07-31 · Edward J. LudwigBought $428,721 on 2026-05-20 · Cheryl Pegus, David C. Habiger, Edward J. LudwigSold $1,758,189 on 2025-12-01 · Arthur C. ButcherBought $9,051,492 on 2026-08-03 · David C. Habiger, Michael F. MahoneySold $15,043,394 on 2026-02-02 · Michael F. Mahoney
Bought, 12 months$10.0M
Sold, 12 months$16.8M
Insiders buying5
Insiders selling2

Boston Scientific insider trading at a glance (Nov 20, 2026): in the past 12 months, 5 insiders bought $10.0M and 2 sold $16.8M of BSX stock on the open market, including a cluster buy that began Jul 31, 2026; P/E 18.5 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

BSX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $14.2M sold (9 trades)Q4 2025Q1 2026: $15.0M sold (2 trades)Q1 2026Q2 2026: $554K bought (4 trades)$554KQ2 2026Q3 2026: $9.5M bought (6 trades)$9.5MQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$9.5M6—0
Q2 2026$554K4—0
Q1 2026—0$15.0M2
Q4 2025—0$14.2M9

Valuation, profit and volume

P/E (trailing)18.5Sector median 25.0
Market value$63.58BMedical Devices
Profit margin16.6%Revenue growth +1.4%
Volume vs. 50-day0.6×Last 5 sessions
Insiders' paper profit−$1.2MOn all tracked purchases -12.2%

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 5 Boston Scientific insiders reported open-market purchases totaling $10.0M, while 2 insiders reported sales totaling $16.8M. The most recent cluster buy began on Jul 31, 2026, when 3 insiders bought a combined $9.4M. Among insiders with enough purchase history to measure, David C. Habiger (Director) has the highest Insider Score at 34. 11 of 11 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

BSX earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 28, 2026 +2.8% None -5.3%S&P -0.0% pending
Jul 29, 2026 +3.2% None -0.1%S&P +0.1% +1.8%
Apr 22, 2026 -4.9% None +10.4%S&P +0.6% -12.0%
Feb 4, 2026 +4.0% Sold $15.0M -15.3%S&P -1.7% -8.1%
Oct 22, 2025 +3.3% Sold $4.9M +2.5%S&P +0.1% -5.4%
Jul 23, 2025 -0.6% None +3.0%S&P +0.9% -0.0%
Apr 23, 2025 +3.8% None +6.4%S&P +3.7% +3.3%
Feb 5, 2025 +4.9% None +1.4%S&P +0.8% -5.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

BSX news sentiment trend

Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.

Not enough news
Insider buying that weekAug 22Sep 12Week of 2026-09-19: 3 headlines, 0 positive, 0 negativeWeek of 2026-09-26: 9 headlines, 1 positive, 1 negativeOct 3Oct 24Nov 14
Last 30 days: 0 headlines, 0 positive, 0 negative

Tone is scored from headline wording only. It describes the news, not where the stock is going.

BSX short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 36% of volume sold short2026-08-27: 51% of volume sold short2026-08-28: 54% of volume sold short2026-08-31: 53% of volume sold short2026-09-01: 45% of volume sold short2026-09-02: 39% of volume sold short2026-09-03: 46% of volume sold short2026-09-04: 38% of volume sold short2026-09-08: 43% of volume sold short2026-09-09: 45% of volume sold short2026-09-10: 41% of volume sold short2026-09-11: 19% of volume sold short2026-09-14: 32% of volume sold short2026-09-15: 41% of volume sold short2026-09-16: 47% of volume sold short2026-09-17: 43% of volume sold short2026-09-18: 46% of volume sold short2026-09-21: 33% of volume sold short2026-09-22: 53% of volume sold short2026-09-23: 45% of volume sold short2026-09-24: 48% of volume sold short2026-09-25: 44% of volume sold short2026-09-28: 44% of volume sold short2026-09-29: 34% of volume sold short2026-09-30: 32% of volume sold short2026-10-01: 45% of volume sold short2026-10-02: 60% of volume sold short2026-10-05: 45% of volume sold short2026-10-06: 46% of volume sold short2026-10-07: 55% of volume sold short2026-10-08: 41% of volume sold short2026-10-09: 30% of volume sold short2026-10-12: 41% of volume sold short2026-10-13: 42% of volume sold short2026-10-14: 44% of volume sold short2026-10-15: 34% of volume sold short2026-10-16: 41% of volume sold short2026-10-19: 35% of volume sold short2026-10-20: 42% of volume sold short2026-10-21: 51% of volume sold short2026-10-22: 54% of volume sold short2026-10-23: 53% of volume sold short2026-10-26: 28% of volume sold short2026-10-27: 23% of volume sold short2026-10-28: 38% of volume sold short2026-10-29: 23% of volume sold short2026-10-30: 27% of volume sold short2026-11-02: 37% of volume sold short2026-11-03: 42% of volume sold short2026-11-04: 37% of volume sold short2026-11-05: 37% of volume sold short2026-11-06: 39% of volume sold short2026-11-09: 45% of volume sold short2026-11-10: 35% of volume sold short2026-11-11: 29% of volume sold short2026-11-12: 31% of volume sold short2026-11-13: 25% of volume sold short2026-11-16: 25% of volume sold short2026-11-17: 25% of volume sold short2026-11-18: 35% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 35%20-day average: 34%Prior 2 months: 42%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded BSX

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 -38.2%
John BoozmanSenate Sold $1,001 - $15,000 Jun 4, 2026Jul 13, 2026 -12.6%
Markwayne MullinSenate Bought $15,001 - $50,000 Dec 29, 2025Jan 16, 2026 -55.4%
John BoozmanSenate Sold $1,001 - $15,000 Dec 17, 2025Jan 13, 2026 -54.8%

BSX stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

What happened after BSX insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Aug 26, 2026Susan E. MoranoDirector$100K +0.4%+0.5% vs S&P-8.8%-9.8% vs S&Ppending
Aug 7, 2026David C. HabigerDirector$100K +5.1%+4.7% vs S&P-8.8%-7.8% vs S&P-9.5%-4.5% vs S&P
Aug 5, 2026Michael F. MahoneyCEO, President$9.0M +7.7%+7.4% vs S&P+0.1%+0.1% vs S&P-8.9%-7.1% vs S&P
Aug 5, 2026David C. HabigerDirector$57K +7.7%+7.4% vs S&P+0.1%+0.1% vs S&P-8.9%-7.1% vs S&P
Aug 3, 2026Edward J. LudwigDirector$227K +4.2%+2.2% vs S&P-0.1%-1.1% vs S&P-8.5%-8.0% vs S&P
May 21, 2026David C. HabigerDirector$251K -14.1%-15.7% vs S&P-22.4%-22.9% vs S&P-9.0%-12.8% vs S&P
May 21, 2026Edward J. LudwigDirector$203K -14.1%-15.7% vs S&P-22.4%-22.9% vs S&P-9.0%-12.8% vs S&P
May 21, 2026Cheryl PegusDirector$100K -14.1%-15.7% vs S&P-22.4%-22.9% vs S&P-9.0%-12.8% vs S&P

Insiders at Boston Scientific

InsiderBoughtSoldLast filingPast buys beat S&PScore
Michael F. MahoneyCEO, President $9.0M $15.0M Nov 6, 2026 1 of 3 —
Joseph Michael FitzgeraldEvp & Group Pres, Cardiology — $9.9M Aug 3, 2026 — —
Ellen M. ZaneDirector — $2.6M May 11, 2026 — —
Arthur C. ButcherEvp& Grp Pres, Medsurg & Apac — $1.8M May 4, 2026 — —
Edward J. LudwigDirector $430K — Aug 3, 2026 4 of 7 33
David C. HabigerDirector $408K — Aug 7, 2026 0 of 2 34
Susan E. MoranoDirector $100K — Aug 26, 2026 — —
Cheryl PegusDirector $100K — May 21, 2026 0 of 1 —
Miriam O'SullivanSvp, Chief Hr Officer — — Nov 3, 2026 — —
Padraig Andrew O'ConnorEvp, Global Operations — — Sep 3, 2026 — —
Emily WoodworthSvp, Global Controller And Cao — — Aug 12, 2026 — —
Jonathan MonsonCFO — — Aug 11, 2026 — —
Jessica L. MegaDirector — — May 11, 2026 — —
Christophe Pierre WeberDirector — — May 11, 2026 — —
David S. WichmannDirector — — May 11, 2026 1 of 1 —
Vance R. BrownEvp, Gc And Corp. Secretary — — Feb 18, 2026 — —

Board links: companies that share insiders with BSX

Directors and executives who filed Form 4s for BSX and another company in the last 12 months.

See the map →
  • RDDTReddit David C. Habiger Director here · Director at RDDT · latest filing Oct 7, 2026
  • SYFSynchrony Financial Ellen M. Zane Director here · Director at SYF · latest filing Nov 18, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

BSX stock: common questions

Are Boston Scientific insiders buying BSX stock?

In the past 12 months, 5 insiders reported open-market purchases of BSX worth $10.0M. The latest was Director Susan E Morano bought $100K of BSX at $49.22 — first open-market purchase in our records.

Are Boston Scientific insiders selling BSX stock?

2 insiders reported sales worth $16.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is BSX's P/E ratio?

BSX trades at about 18.5 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is BSX's 52-week range?

Over the past year BSX has traded between $41.58 and $101.58. It last closed at $42.72 on Nov 20, 2026.